Combination Therapy of Interferon Alfa-2b Plus Interleukin 2 and Hepatitis B Vaccine in Entecavir-experienced Chronic Hepatitis B Patients With HBeAg Seroclearance: a Prospective, Randomized Open-label Trial (Endeavor Study, a Pilot Study)

Trial Profile

Combination Therapy of Interferon Alfa-2b Plus Interleukin 2 and Hepatitis B Vaccine in Entecavir-experienced Chronic Hepatitis B Patients With HBeAg Seroclearance: a Prospective, Randomized Open-label Trial (Endeavor Study, a Pilot Study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Entecavir (Primary) ; Hepatitis B vaccines; Interferon alpha-2b; Interleukin-2
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ENDEAVOR
  • Most Recent Events

    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 15 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Jun 2017.
    • 15 Jun 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top